162 related articles for article (PubMed ID: 20574851)
1. Protein-based MRI contrast agents for molecular imaging of prostate cancer.
Wei L; Li S; Yang J; Ye Y; Zou J; Wang L; Long R; Zurkiya O; Zhao T; Johnson J; Qiao J; Zhou W; Castiblanco A; Maor N; Chen Y; Mao H; Hu X; Yang JJ; Liu ZR
Mol Imaging Biol; 2011 Jun; 13(3):416-423. PubMed ID: 20574851
[TBL] [Abstract][Full Text] [Related]
2. GRPR-targeted Protein Contrast Agents for Molecular Imaging of Receptor Expression in Cancers by MRI.
Pu F; Qiao J; Xue S; Yang H; Patel A; Wei L; Hekmatyar K; Salarian M; Grossniklaus HE; Liu ZR; Yang JJ
Sci Rep; 2015 Nov; 5():16214. PubMed ID: 26577829
[TBL] [Abstract][Full Text] [Related]
3. ProCA1.GRPR: a new imaging agent in cancer detection.
Pu F; Xue S; Yang JJ
Biomark Med; 2016 May; 10(5):449-52. PubMed ID: 27071673
[No Abstract] [Full Text] [Related]
4. In vivo MR/optical imaging for gastrin releasing peptide receptor of prostate cancer tumor using Gd-TTDA-NP-BN-Cy5.5.
Lin YH; Dayananda K; Chen CY; Liu GC; Luo TY; Hsu HS; Wang YM
Bioorg Med Chem; 2011 Feb; 19(3):1085-96. PubMed ID: 20493715
[TBL] [Abstract][Full Text] [Related]
5. MR molecular imaging of prostate cancer with a peptide-targeted contrast agent in a mouse orthotopic prostate cancer model.
Tan M; Burden-Gulley SM; Li W; Wu X; Lindner D; Brady-Kalnay SM; Gulani V; Lu ZR
Pharm Res; 2012 Apr; 29(4):953-60. PubMed ID: 22139536
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Assessment of Peptide Gd-DOTA Conjugates Targeting Extradomain B Fibronectin for Magnetic Resonance Molecular Imaging of Prostate Cancer.
Li Y; Han Z; Roelle S; DeSanto A; Sabatelle R; Schur R; Lu ZR
Mol Pharm; 2017 Nov; 14(11):3906-3915. PubMed ID: 28976766
[TBL] [Abstract][Full Text] [Related]
7. MR molecular imaging of prostate cancer with a small molecular CLT1 peptide targeted contrast agent.
Wu X; Lindner D; Yu GP; Brady-Kalnay S; Lu ZR
J Vis Exp; 2013 Sep; (79):. PubMed ID: 24056726
[TBL] [Abstract][Full Text] [Related]
8. Gastrin-releasing peptide receptor-targeted gadolinium oxide-based multifunctional nanoparticles for dual magnetic resonance/fluorescent molecular imaging of prostate cancer.
Cui D; Lu X; Yan C; Liu X; Hou M; Xia Q; Xu Y; Liu R
Int J Nanomedicine; 2017; 12():6787-6797. PubMed ID: 28979118
[TBL] [Abstract][Full Text] [Related]
9. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
[TBL] [Abstract][Full Text] [Related]
10. The gastrin/cholecystokinin-B receptor on prostate cells--a novel target for bifunctional prostate cancer imaging.
Sturzu A; Klose U; Sheikh S; Echner H; Kalbacher H; Deeg M; Nägele T; Schwentner C; Ernemann U; Heckl S
Eur J Pharm Sci; 2014 Feb; 52():69-76. PubMed ID: 24211650
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer.
Richter S; Wuest M; Krieger SS; Rogers BE; Friebe M; Bergmann R; Wuest F
Nucl Med Biol; 2013 Nov; 40(8):1025-34. PubMed ID: 23969085
[TBL] [Abstract][Full Text] [Related]
12. Targeted Contrast Agent Specific to an Oncoprotein in Tumor Microenvironment with the Potential for Detection and Risk Stratification of Prostate Cancer with MRI.
Han Z; Li Y; Roelle S; Zhou Z; Liu Y; Sabatelle R; DeSanto A; Yu X; Zhu H; Magi-Galluzzi C; Lu ZR
Bioconjug Chem; 2017 Apr; 28(4):1031-1040. PubMed ID: 28201871
[TBL] [Abstract][Full Text] [Related]
13. Metabolically Stabilized (68)Ga-NOTA-Bombesin for PET Imaging of Prostate Cancer and Influence of Protease Inhibitor Phosphoramidon.
Richter S; Wuest M; Bergman CN; Krieger S; Rogers BE; Wuest F
Mol Pharm; 2016 Apr; 13(4):1347-57. PubMed ID: 26973098
[TBL] [Abstract][Full Text] [Related]
14. Targeted Molecular Iron Oxide Contrast Agents for Imaging Atherosclerotic Plaque.
Evans RJ; Lavin B; Phinikaridou A; Chooi KY; Mohri Z; Wong E; Boyle JJ; Krams R; Botnar R; Long NJ
Nanotheranostics; 2020; 4(4):184-194. PubMed ID: 32637296
[No Abstract] [Full Text] [Related]
15. Synthesis and characterization of Bombesin-superparamagnetic iron oxide nanoparticles as a targeted contrast agent for imaging of breast cancer using MRI.
Jafari A; Salouti M; Shayesteh SF; Heidari Z; Rajabi AB; Boustani K; Nahardani A
Nanotechnology; 2015 Feb; 26(7):075101. PubMed ID: 25642737
[TBL] [Abstract][Full Text] [Related]
16. The Utility of [
Beinat C; Haywood T; Chen YS; Patel CB; Alam IS; Murty S; Gambhir SS
Mol Imaging Biol; 2018 Dec; 20(6):1015-1024. PubMed ID: 29736561
[TBL] [Abstract][Full Text] [Related]
17. Quantitative Molecular Imaging with a Single Gd-Based Contrast Agent Reveals Specific Tumor Binding and Retention in Vivo.
Johansen ML; Gao Y; Hutnick MA; Craig SEL; Pokorski JK; Flask CA; Brady-Kalnay SM
Anal Chem; 2017 Jun; 89(11):5932-5939. PubMed ID: 28481080
[TBL] [Abstract][Full Text] [Related]
18. Dynamic Contrast-Enhanced Imaging as a Prognostic Tool in Early Diagnosis of Prostate Cancer: Correlation with PSA and Clinical Stage.
Wu X; Reinikainen P; Kapanen M; Vierikko T; Ryymin P; Kellokumpu-Lehtinen PL
Contrast Media Mol Imaging; 2018; 2018():3181258. PubMed ID: 30327584
[TBL] [Abstract][Full Text] [Related]
19. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy.
Haider MA; Chung P; Sweet J; Toi A; Jhaveri K; Ménard C; Warde P; Trachtenberg J; Lockwood G; Milosevic M
Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):425-30. PubMed ID: 17881141
[TBL] [Abstract][Full Text] [Related]
20. A comparative PET imaging study of
Ferguson S; Wuest M; Richter S; Bergman C; Dufour J; Krys D; Simone J; Jans HS; Riauka T; Wuest F
Nucl Med Biol; 2020; 90-91():74-83. PubMed ID: 33189947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
